Last edition
News about "Objective Response Rate (ORR) "
Sanofi Secures Japan Approval for Subcutaneous Formulation of Sarclisa
Sanofi’s Sarclisa subcutaneous formulation has been approved in Japan for patients with multiple myeloma. The approval is supported by the Phase 3 IRAKLIA study and marks the second global approval after the EU.
Objective Response Rate (ORR) | 22/06/2026 | By News Bureau
Mabwell Presents Clinical Data for Nectin-4 ADC 9MW2821 at ESMO 2026
Clinical studies presented at the 2026 ESMO Gynecological Cancers Congress showed that Mabwell’s Nectin-4-targeting ADC 9MW2821 demonstrated a manageable safety profile, promising efficacy, and notable survival benefits in cervical cancer patients, with encouraging antitumor activity when combined with a PD-1 inhibitor.
Objective Response Rate (ORR) | 20/06/2026 | By News Bureau | 117
Pfizer's BRAFTOVI Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported phase 3 BREAKWATER trial results showing that the BRAFTOVI regimen nearly doubled median Progression-Free Survival (PFS) in patients with metastatic colorectal cancer, reducing the risk of disease progression or death by 56 percent and the risk of death by 44 percent compared with standard chemotherapy in BRAF V600E-mutant disease.
Objective Response Rate (ORR) | 01/06/2026 | By News Bureau
Pfizer Reports Improved Response Rates with BRAFTOVI Regimen in Metastatic Colorectal Cancer
New data from the BREAKWATER study show that Pfizer’s BRAFTOVI-based regimen significantly improved response rates in patients with BRAF V600E–mutant metastatic colorectal cancer, supporting the potential use of flexible chemotherapy backbones.
Objective Response Rate (ORR) | 12/01/2026 | By News Bureau | 149
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Objective Response Rate (ORR) | 15/11/2025 | By Dineshwori | 322
Merck KGaA Reports Sustained Efficacy and Safety of OGSIVEO in Phase-III Desmoid Tumour Study
Merck KGaA has released long-term phase-III data showing that OGSIVEO treatment for up to four years continues to deliver durable tumour reductions, improved response rates, sustained symptom relief, and a consistent safety profile in patients with desmoid tumours.
Objective Response Rate (ORR) | 27/10/2025 | By Dineshwori | 308
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy